The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2026:


	Life Sciences and Diagnostics Markets		Agilent CrossLab		Applied Markets		Total
	(in millions)
Goodwill as of October 31, 2025	$	2,996	$	1,168	$	309	$	4,473
Foreign currency translation impact	—		3		5		8
Goodwill arising from acquisitions	549		—		—		549
Goodwill as of July 31, 2026	$	3,545	$	1,171	$	314	$	5,030


	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2025
Purchased technology	$	1,484	$	1,235	$	249
Trademark/Trade name	199		181		18
Customer relationships	289		129		160
Backlog	9		2		7
Third-party technology and licenses	34		23		11


Total amortizable intangible assets	$	2,015	$	1,570	$	445
As of July 31, 2026
Purchased technology	$	1,633	$	1,269	$	364
Trademark/Trade name	201		185		16
Customer relationships	660		148		512
Backlog	9		3		6
Third-party technology and licenses	35		27		8


Total amortizable intangible assets	$	2,538	$	1,632	$	906

During the nine months ended July 31, 2026, we recorded additions of $549 million to goodwill and $520 million to other intangible assets in our Life Sciences and Diagnostics Markets segment related to our acquisition of Biocare. During the nine months ended July 31, 2026, there was no change in net book value of other intangible assets due to the impact of foreign currency translation.

In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible.

Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and nine months ended July 31, 2026 and 2025, we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets.

For the three and nine months ended July 31, 2026, amortization expense of intangible assets was $21 million and $59 million, respectively. For the three and nine months ended July 31, 2025, amortization expense of intangible assets was $26 million and $81 million, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2026 and for each of the next five fiscal years and thereafter is estimated below:


Estimated future amortization expense:
	(in millions)
Remainder of 2026	$	27
2027	$	108
2028	$	101
2029	$	97
2030	$	87
2031	$	81
Thereafter	$	405